(April 20, 2021, 9:06 AM EDT) -- NEWARK, N.J. — A biotechnology company and three of its former senior executives violated federal securities laws by issuing a series of misrepresentations regarding the expected financial windfall of two new drugs in its inflammation and immunology (I&I) franchise, causing the company’s stock to trade at an artificially high rate, a shareholder alleges in an April 16 complaint filed in a New Jersey federal court....